- Home
- CCM vs NRXP Comparison
CCM vs NRXP Comparison
Compare CCM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- NRXP
- Stock Information
- Founded
- CCM 1997
- NRXP 2015
- Country
- CCM China
- NRXP United States
- Employees
- CCM N/A
- NRXP N/A
- Industry
- CCM Medical/Nursing Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CCM Health Care
- NRXP Health Care
- Exchange
- CCM Nasdaq
- NRXP Nasdaq
- Market Cap
- CCM 33.3M
- NRXP 32.6M
- IPO Year
- CCM 2009
- NRXP N/A
- Fundamental
- Price
- CCM $5.49
- NRXP $3.50
- Analyst Decision
- CCM
- NRXP Strong Buy
- Analyst Count
- CCM 0
- NRXP 4
- Target Price
- CCM N/A
- NRXP $28.50
- AVG Volume (30 Days)
- CCM 4.4K
- NRXP 295.0K
- Earning Date
- CCM 04-25-2025
- NRXP 08-13-2025
- Dividend Yield
- CCM N/A
- NRXP N/A
- EPS Growth
- CCM N/A
- NRXP N/A
- EPS
- CCM N/A
- NRXP N/A
- Revenue
- CCM $52,603,198.00
- NRXP N/A
- Revenue This Year
- CCM N/A
- NRXP N/A
- Revenue Next Year
- CCM N/A
- NRXP N/A
- P/E Ratio
- CCM N/A
- NRXP N/A
- Revenue Growth
- CCM N/A
- NRXP N/A
- 52 Week Low
- CCM $3.80
- NRXP $1.10
- 52 Week High
- CCM $10.90
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- CCM 36.56
- NRXP 66.15
- Support Level
- CCM $4.91
- NRXP $2.90
- Resistance Level
- CCM $6.47
- NRXP $3.61
- Average True Range (ATR)
- CCM 0.31
- NRXP 0.28
- MACD
- CCM -0.17
- NRXP -0.03
- Stochastic Oscillator
- CCM 24.68
- NRXP 64.59
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.